Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in <i>Aspergillus fumigatus</i>.

ABSTRACT: The rising rates of triazole drug resistance in Aspergillus fumigatus have placed greater reliance on antifungal susceptibility testing (AFST) to guide therapeutic management, particularly in medically complicated patients. Current methods, however, utilize conventional phenotypic assays that may pose significant challenges in performance, result interpretation, and time to reporting. Herein, we developed and validated a next-generation sequencing-based clinical test to predict the AFST phenotype of A. fumigatus against voriconazole, posaconazole, isavuconazole, and itraconazole using the cyp51A genotype as a marker for susceptibility. We sequenced 109 isolates comprising reference and clinical samples from the University of California, Los Angeles, Clinical Microbiolo

SUBMITTER: Caldera JR 

PROVIDER: S-EPMC12345187 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature